A continuation of “DeFi Exploited for Over $630 Million So Far in 2026”In July, I wrote about the risks DeFi protocols inherit when core functionality relies on external systems. That article focuses primarily on oracle manipulation, keepers and offchain verifiers. Hooks were included, but they weren’t the center of it, mainly because the data didn’t exist, or I at least hadn’t come across it yet. Then 0x published an article titled “Uniswap v4 hooks were a mistake,” based on its analysis of 84,

Kapil Nema, Deputy Executive Director-Sugar & Ethanol Business at Dalmia Bharat Sugar & Industries expects inventories at 5–5.5 million tonne, while recent rains could impact output in Uttar Pradesh, Maharashtra and Karnataka. Globally, lower Brazilian crushing is supporting prices. Nema also expects no sugar diversion to ethanol in the first tender cycle until there is greater clarity on the crop.

Indian shares opened marginally higher on Tuesday, extending their rebound from the previous session, led by banks on positive quarterly updates, while supportive global cues aided sentiment ahead of...

Stock Market Today (October 6): GIFT Nifty Futures indicated a flat start to the trading day as experts tracked US trade deal hurdles and keep an eye on RBI's policy decision., Markets, Times Now

Moonshot AI plans a Hong Kong IPO in early 2027 after reaching a US$50 billion valuation, aiming to raise up to US$5 billion amid regulatory reviews. Read more at straitstimes.com.

Built with input from J. P. Morgan, the open-source "DvP" program lets institutions settle trades atomically on Solana with finality in seconds instead of days.

S&P/ASX 200 Index (ASX: XJO) shares are in the green today as we review some expert views and ratings on NextDC Ltd (ASX: NXT) and 2 others.

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Blaize Holdings, Inc. (Nasdaq: BZAI; BZAIW) ('Blaize” or the 'Company”), a leader in programmable, energy-efficient AI computing, today announced its preliminary third quarter 2026 revenue. The Company also provided an update regarding its previously issued full-year 2026 revenue guidance. These matters are further described in a Current Report on Form 8-K filed today with the U.S. Securities and Exchange Commission.

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ('Spyre” or the 'Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to